{
  "trial_id": "NCT01441973",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, race, baseline serum monoclonal (M) protein level, baseline bone marrow plasma cells (BMPC) percentage, baseline free light chain ratio, baseline urine M protein level, baseline CD56^dim cells percentage, performance status, prior treatments, comorbidities.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "gender"
        ],
        [
          "BMPC percentage",
          "baseline bone marrow plasma cells (BMPC) percentage"
        ],
        [
          "Serum M protein",
          "baseline serum monoclonal (M) protein level"
        ],
        [
          "Urine M protein",
          "baseline urine M protein level"
        ]
      ],
      "remaining_reference_features": [
        "Myeloma type",
        "ECOG performance status",
        "Serum \u03b22 microglobulin",
        "Chronic kidney disease stage",
        "Time since diagnosis",
        "Satisfied high\u2010risk SMM criteria at study entry"
      ],
      "remaining_candidate_features": [
        "race",
        "baseline free light chain ratio",
        "baseline CD56^dim cells percentage",
        "performance status",
        "prior treatments",
        "comorbidities"
      ]
    },
    "processed-gen-response": "Age, gender, race, baseline serum monoclonal (M) protein level, baseline bone marrow plasma cells (BMPC) percentage, baseline free light chain ratio, baseline urine M protein level, baseline CD56^dim cells percentage, performance status, prior treatments, comorbidities."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Sex, Race, Serum monoclonal (M) protein level, Bone marrow plasma cells (BMPC) percentage, Serum free light chain ratio, Urine M protein level, Hepatitis B/C status, HIV status",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "Sex"
        ],
        [
          "BMPC percentage",
          "Bone marrow plasma cells (BMPC) percentage"
        ],
        [
          "Serum M protein",
          "Serum monoclonal (M) protein level"
        ],
        [
          "Urine M protein",
          "Urine M protein level"
        ]
      ],
      "remaining_reference_features": [
        "Myeloma type",
        "ECOG performance status",
        "Serum \u03b22 microglobulin",
        "Chronic kidney disease stage",
        "Time since diagnosis",
        "Satisfied high\u2010risk SMM criteria at study entry"
      ],
      "remaining_candidate_features": [
        "Race",
        "Serum free light chain ratio",
        "Hepatitis B/C status",
        "HIV status"
      ]
    },
    "processed-gen-response": "Age, Sex, Race, Serum monoclonal (M) protein level, Bone marrow plasma cells (BMPC) percentage, Serum free light chain ratio, Urine M protein level, Hepatitis B/C status, HIV status"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Sex, Race, BMI, Serum monoclonal (M) protein, Bone marrow plasma cells (BMPC), Urine M protein, Serum free light chain ratio, Hepatitis B or C virus or HIV infection status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "Sex"
        ],
        [
          "BMPC percentage",
          "Bone marrow plasma cells (BMPC)"
        ],
        [
          "Serum M protein",
          "Serum monoclonal (M) protein"
        ],
        [
          "Urine M protein",
          "Urine M protein"
        ]
      ],
      "remaining_reference_features": [
        "Myeloma type",
        "ECOG performance status",
        "Serum \u03b22 microglobulin",
        "Chronic kidney disease stage",
        "Time since diagnosis",
        "Satisfied high\u2010risk SMM criteria at study entry"
      ],
      "remaining_candidate_features": [
        "Race",
        "BMI",
        "Serum free light chain ratio",
        "Hepatitis B or C virus or HIV infection status."
      ]
    },
    "processed-gen-response": "Age, Sex, Race, BMI, Serum monoclonal (M) protein, Bone marrow plasma cells (BMPC), Urine M protein, Serum free light chain ratio, Hepatitis B or C virus or HIV infection status."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), serum monoclonal (M) protein level, bone marrow plasma cells (BMPC) percentage, free light chain ratio, urine M protein level, presence of cytogenetic abnormalities, prior therapies, duration of smoldering multiple myeloma, Eastern Cooperative Oncology Group (ECOG) performance status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "sex"
        ],
        [
          "ECOG performance status",
          "Eastern Cooperative Oncology Group (ECOG) performance status"
        ],
        [
          "BMPC percentage",
          "bone marrow plasma cells (BMPC) percentage"
        ],
        [
          "Serum M protein",
          "serum monoclonal (M) protein level"
        ],
        [
          "Urine M protein",
          "urine M protein level"
        ],
        [
          "Time since diagnosis",
          "duration of smoldering multiple myeloma"
        ]
      ],
      "remaining_reference_features": [
        "Myeloma type",
        "Serum \u03b22 microglobulin",
        "Chronic kidney disease stage",
        "Satisfied high\u2010risk SMM criteria at study entry"
      ],
      "remaining_candidate_features": [
        "race",
        "ethnicity",
        "body mass index (BMI)",
        "free light chain ratio",
        "presence of cytogenetic abnormalities",
        "prior therapies"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, body mass index (BMI), serum monoclonal (M) protein level, bone marrow plasma cells (BMPC) percentage, free light chain ratio, urine M protein level, presence of cytogenetic abnormalities, prior therapies, duration of smoldering multiple myeloma, Eastern Cooperative Oncology Group (ECOG) performance status."
  }
}